Cargando…

Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma

Multiple myeloma (MM) is a dyscrasia of plasma cells (PCs) characterized by abnormal immunoglobulin (Ig) production. The disease remains incurable due to a multitude of mutations and structural abnormalities in MM cells, coupled with a favorable microenvironment and immune suppression that eventuall...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Niyati Seshagiri, Choudhary, Bibha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669790/
https://www.ncbi.nlm.nih.gov/pubmed/38002311
http://dx.doi.org/10.3390/biom13111629
_version_ 1785139775346311168
author Sharma, Niyati Seshagiri
Choudhary, Bibha
author_facet Sharma, Niyati Seshagiri
Choudhary, Bibha
author_sort Sharma, Niyati Seshagiri
collection PubMed
description Multiple myeloma (MM) is a dyscrasia of plasma cells (PCs) characterized by abnormal immunoglobulin (Ig) production. The disease remains incurable due to a multitude of mutations and structural abnormalities in MM cells, coupled with a favorable microenvironment and immune suppression that eventually contribute to the development of drug resistance. The bone marrow microenvironment (BMME) is composed of a cellular component comprising stromal cells, endothelial cells, osteoclasts, osteoblasts, and immune cells, and a non-cellular component made of the extracellular matrix (ECM) and the liquid milieu, which contains cytokines, growth factors, and chemokines. The bone marrow stromal cells (BMSCs) are involved in the adhesion of MM cells, promote the growth, proliferation, invasion, and drug resistance of MM cells, and are also crucial in angiogenesis and the formation of lytic bone lesions. Classical immunophenotyping in combination with advanced immune profiling using single-cell sequencing technologies has enabled immune cell-specific gene expression analysis in MM to further elucidate the roles of specific immune cell fractions from peripheral blood and bone marrow (BM) in myelomagenesis and progression, immune evasion and exhaustion mechanisms, and development of drug resistance and relapse. The review describes the role of BMME components in MM development and ongoing clinical trials using immunotherapeutic approaches.
format Online
Article
Text
id pubmed-10669790
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106697902023-11-07 Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma Sharma, Niyati Seshagiri Choudhary, Bibha Biomolecules Review Multiple myeloma (MM) is a dyscrasia of plasma cells (PCs) characterized by abnormal immunoglobulin (Ig) production. The disease remains incurable due to a multitude of mutations and structural abnormalities in MM cells, coupled with a favorable microenvironment and immune suppression that eventually contribute to the development of drug resistance. The bone marrow microenvironment (BMME) is composed of a cellular component comprising stromal cells, endothelial cells, osteoclasts, osteoblasts, and immune cells, and a non-cellular component made of the extracellular matrix (ECM) and the liquid milieu, which contains cytokines, growth factors, and chemokines. The bone marrow stromal cells (BMSCs) are involved in the adhesion of MM cells, promote the growth, proliferation, invasion, and drug resistance of MM cells, and are also crucial in angiogenesis and the formation of lytic bone lesions. Classical immunophenotyping in combination with advanced immune profiling using single-cell sequencing technologies has enabled immune cell-specific gene expression analysis in MM to further elucidate the roles of specific immune cell fractions from peripheral blood and bone marrow (BM) in myelomagenesis and progression, immune evasion and exhaustion mechanisms, and development of drug resistance and relapse. The review describes the role of BMME components in MM development and ongoing clinical trials using immunotherapeutic approaches. MDPI 2023-11-07 /pmc/articles/PMC10669790/ /pubmed/38002311 http://dx.doi.org/10.3390/biom13111629 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Sharma, Niyati Seshagiri
Choudhary, Bibha
Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma
title Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma
title_full Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma
title_fullStr Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma
title_full_unstemmed Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma
title_short Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma
title_sort good cop, bad cop: profiling the immune landscape in multiple myeloma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669790/
https://www.ncbi.nlm.nih.gov/pubmed/38002311
http://dx.doi.org/10.3390/biom13111629
work_keys_str_mv AT sharmaniyatiseshagiri goodcopbadcopprofilingtheimmunelandscapeinmultiplemyeloma
AT choudharybibha goodcopbadcopprofilingtheimmunelandscapeinmultiplemyeloma